1. Home
  2. EDIT vs HYI Comparison

EDIT vs HYI Comparison

Compare EDIT & HYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDIT
  • HYI
  • Stock Information
  • Founded
  • EDIT 2013
  • HYI 2010
  • Country
  • EDIT United States
  • HYI United States
  • Employees
  • EDIT N/A
  • HYI N/A
  • Industry
  • EDIT Biotechnology: Biological Products (No Diagnostic Substances)
  • HYI Investment Managers
  • Sector
  • EDIT Health Care
  • HYI Finance
  • Exchange
  • EDIT Nasdaq
  • HYI Nasdaq
  • Market Cap
  • EDIT 269.8M
  • HYI 272.7M
  • IPO Year
  • EDIT 2016
  • HYI N/A
  • Fundamental
  • Price
  • EDIT $4.01
  • HYI $11.48
  • Analyst Decision
  • EDIT Buy
  • HYI
  • Analyst Count
  • EDIT 11
  • HYI 0
  • Target Price
  • EDIT $4.56
  • HYI N/A
  • AVG Volume (30 Days)
  • EDIT 3.3M
  • HYI 50.6K
  • Earning Date
  • EDIT 11-03-2025
  • HYI 01-01-0001
  • Dividend Yield
  • EDIT N/A
  • HYI 9.59%
  • EPS Growth
  • EDIT N/A
  • HYI N/A
  • EPS
  • EDIT N/A
  • HYI N/A
  • Revenue
  • EDIT $38,901,000.00
  • HYI N/A
  • Revenue This Year
  • EDIT N/A
  • HYI N/A
  • Revenue Next Year
  • EDIT N/A
  • HYI N/A
  • P/E Ratio
  • EDIT N/A
  • HYI N/A
  • Revenue Growth
  • EDIT N/A
  • HYI N/A
  • 52 Week Low
  • EDIT $0.91
  • HYI $10.99
  • 52 Week High
  • EDIT $4.54
  • HYI $12.24
  • Technical
  • Relative Strength Index (RSI)
  • EDIT 63.02
  • HYI 32.69
  • Support Level
  • EDIT $3.32
  • HYI $11.44
  • Resistance Level
  • EDIT $4.29
  • HYI $11.69
  • Average True Range (ATR)
  • EDIT 0.35
  • HYI 0.11
  • MACD
  • EDIT -0.01
  • HYI -0.01
  • Stochastic Oscillator
  • EDIT 63.19
  • HYI 10.87

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

About HYI Western Asset High Yield Defined Opportunity Fund Inc.

Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.

Share on Social Networks: